American Journal of Cardiology
Volume 105, Issue 6 , Pages 786-791 , 15 March 2010

Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease

  • Gregory A. Nichols, PhD

      Affiliations

    • Kaiser Permanente, Center for Health Research, Portland, Oregon
    • Corresponding Author InformationCorresponding author: Tel: (503) 335-6733; fax: (503) 335-6311
    • ,
  • Fang Wang, MD, PhD

      Affiliations

    • GlaxoSmithKline, Incorporated, King of Prussia, Pennsylvania
    • ,
  • Kathryn L. Pedula, MS

      Affiliations

    • Kaiser Permanente, Center for Health Research, Portland, Oregon

Received 17 September 2009 ,Revised 5 November 2009 ,Accepted 5 November 2009.

References 

  1. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363–2372
  2. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058–2068
  3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  4. Kastelein JJP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009
  5. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14:271–280
  6. Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. Am Heart J. 2006;151:969–975
  7. Doyle F, De La Harpe D, McGee H, Shelley E, Conroy R. Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions. Eur J Cardiovasc Prev Rehabil. 2005;12:376–379
  8. Birkhead JS, Weston C, Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004–2005: observational study. BMJ. 2006;332:1306–1311
  9. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116
  10. Manjunath M, Sarnak M, Levey A. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens. 2001;10:785–792
  11. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. Cary: North Carolina: SAS Institute; 2000;
  12. Steg PG, Bhatt DL, Wilson PWF, D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206
  13. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1:38–45
  14. Eagle KA, Montoye CK, Riba AL, DeFranco AC, Parrish R, Skorcz S, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol. 2005;46:1242–1248
  15. Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard JM, Agnelli G, et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2007;100:1–6
  16. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109:745–749
  17. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved Treatment of Coronary Heart Disease by Implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–922
  18. Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008;149:612–617
  19. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485–488
  20. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–1152
  21. Kramer JM, Hammill B, Anstrom KJ, Fetteroff D, Snyder R, Charde JP, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454.e1–454.e8
  22. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118:576–585
  23. Robinson JG, Maheshwari N. A “poly-portfolio” for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol. 2005;95:373–378

 This study was funded by GlaxoSmithKline, King of Prussia, Pennsylvania. Dr. Nichols has received research support from Amgen, Incorporated (Thousand Oaks, California), Novo Nordisk (Bagsvaerd, Denmark), Novartis Pharmaceuticals (Basel, Switzerland), Tethys BioScience, Incorporated (Emeryville, California), and Merck & Company, Incorporated (Whitehouse Station, New Jersey).

 Dr. Wang is a GlaxoSmithKline employee.

 By contract and in accordance with the Uniform Requirements for Biomedical Journal submissions, Dr. Nichols had the final say in the design, interpretation, and presentation of the data and text.

PII: S0002-9149(09)02677-0

doi: 10.1016/j.amjcard.2009.11.008

American Journal of Cardiology
Volume 105, Issue 6 , Pages 786-791 , 15 March 2010

Article Tools

* Image Usage & Resolution